no patent for novartis. india possibly in court has dismissed the patent protection plea for its cancer drug, greenback -- glivec. >> it is a serious blow not just for novartis, but for other western firms as well. they have been focusing on india to drive sales at a time when the global climate is not as rewarding. >> the ruling is a win worldwide for patients and dramatic -- genetic drugmakers. >> india had one word for novartis -- no. judges would not let them take out patrons for -- patents for old drugs with new tweaks. bad news for novartis. >> patents will only be granted for genuine inventions. >> it is a victory for protesters like these, who say pharmaceutical patent's -- patents cost lives. novartis's medication cost around 1700 euros per month. many, if -- for many, it is generic medication or none at all. in a radio interview, the company's chief of corporate research can't be ruling a setback for research and for india. -- called the ruling a setback for research and for india. >> for novartis,

no patent for novartis. india possibly in court has dismissed the patent protection plea for its cancer drug, greenback -- glivec. >> it is a serious blow not just for novartis, but for other western firms as well. they have been focusing on india to drive sales at a time when the global climate is not as rewarding. >> the ruling is a win worldwide for patients and dramatic -- genetic drugmakers. >> india had one word for novartis -- no. judges would not let them take out patrons for -- patents for old drugs with new tweaks. bad news for novartis. >> patents will only be granted for genuine inventions. >> it is a victory for protesters like these, who say pharmaceutical patent's -- patents cost lives. novartis's medication cost around 1700 euros per month. many, if -- for many, it is generic medication or none at all. in a radio interview, the company's chief of corporate research can't be ruling a setback for research and for india. -- called the ruling a setback for research and for india. >> for novartis,

it dismissed a patent claim from the swiss drug company novartis. in the city of timbuktu, on high alert after fighting broke out over the weekend, violence which also fired up in another city. comes nearly three months after france began operations to drive rebels out of the country's north. the islam list fighters, actually, they have not been named. they have not announced their identity. they entered a house next to the anddquarters in timbuktu, they could not get into the house. according to our source, a french aircraft bombarded that house. it is believed that they were killed in that raid. we also understand that some soldiers from mali are being treated in the medical center in timbuktu. the same source says that at least one french man, they did not know if this man was a soldier or was wounded or killed in the attack. >> the president of sudan says he will release all political prisoners and talk with opposition groups. he made an announcement in a speech opening a new session of parliament. they have demanding for almost two years that t

this is the second wave of charges against novartis in just one week.uthorities now saying that for a decade the swiss drug maker paid millions to doctors in exchange for spearing patients towards its drugs. according to prosecutors, not much education was going on. here's what the u.s. attorney has to say. novartis corrupted the prescription drug dispensing process with programs that steroid patients towards its drugs. novartis disagrees with the way the government has characterized their conduct and stands behind their programs. >> the question tonight is what would stop companies from doing this. if being find is the only punishment, not much, because'ge all know that marketing budgets are very large and these kind of things can make or break moments for drug makers. and guys, right now we're just talking about civil charges. >> all right, so taking doctors out to dinner, that seems pretty innocent. what was wrong here? >> it's perfectly fine to take doctors out to dinner. but in this case there are strict guidelines that must be followed. and in thi

this is the second wave of charges against novartis in just one week.ties now saying that for a decade, the swiss drug maker paid millions to doctors in exchange for steering patients towards its drugs. now, here's what the u.s. attorney had to say about the whole thing. novartis corrupted the prescription drug dispensing process with multi-million dollar incentive programs that targeted doctors, who in exchange for illegal kickbacks steered patients towards its drugs. novartis in its statement disagrees in the way the government is characterizing them. back to you, larry. >> i appreciate it. why is it the obama administration hates business? what? wrong with going to hooters, what's wrong with taking a couple young doctors to hooters to have a hamburger? i think the obama administration hates drug companies. they also hate health insurance companies. you know what is a close third, they especially hate oil and gas. all right. that's really something. you know in this company, work in the private sector, sales people take their clients out to dinner all

novartis claimed it had made the drug more effective and thus warrented a new patent. india's supreme court disagreed. the ruling allows indian companies to make copycat versions. "if the drug companies aren't able to have patent protection, maybe not in every country but in most countries, they're not going to be able to make back the sums on money it takes to develop drugs." pharmaceutical researchers and manufacturers of america, a trade group, says, "the indian courts have come down on the side that doesn't recognize the value of innovation and the value of strong intellectual property." however, analysts doubt the ruling will influence decisions beyond india, nor do they think it will affect the overall profitability of large pharmaceutical companies. "overall, we still think the pharmaceutical fundamentals look quite good. from a valuation standpoint, a lot of stocks have run quite a bit, and there aren't a lot that we think are extremely undervalued." nonetheless, novartis claims the ruling discourages it from introducing new drugs in india, despite a market of

novartis disputes the claims. the government is suing lance armstrong.the department of justice accuses the armstrong team of "regularly employing banned substances and methods to enhance their performance..." the deparment the team took more than $30 million in sponsor money from the u.s. postal service, then used prohibited drugs.armstrong's attorney calls the lawsuit "opportunitstic. " a study about traffic congestion is clearing up a few things about the economy. data company inrix finds that -- to no surpise-- los angeles continues to have the heaviest traffic jams in the country. followed by honolulu and san francisco. jim bak of inrix says the rise in traffic indicates more people are on the roads for work. "in 2013, hiring is back again for the most part, and as a result we are seeing traffic back. and now 61 of the 100 worst cities for traffic are now on the rise, and we are seeing unemployment in those cities receding back to levels not seen since the recession." congestion in major u.s. cities has incre

drug giant novartis is defending itself against allegations of kickback schemes. a federal lawsuit alleges novartis of bribing doctors with money, trips, and outings at hooters restaurants. novartis tells the wall street journal that "discounts and rebates by pharmaceutical companies are a customary, appropriate and legal practice as recognized by the government itself." the government says kickback schemes raise the cost of healthcare for everyone. google is trying its hand at digital assistance as it attempts to upstage apple's siri. yesterday, google released a new free app called google now. it performs many of the tasks that apple's siri does. google says its app is superior to siri becasue of its ability to anticipate a user's needs. in other tech news, samsung unveiled its galaxy 3 tablet yesterday. this new model uses the latest android operating system and will be available worldwide next month. ahead of its u.s. opening, "iron man 3" already has ironclad box office numbers abroad. the third installment of the superhero series raked in $195 million when i

in the ruling handed down on monday, the court says the compound made by novartis is not novel enough to qualify for a patent. the company filed the case seven years ago. india has it stricter pharmaceutical patent requirements than other nations. for example it doesn't allow patents for twaeks to existing drugs. this practice is known as evergreening. india is a major producer of copycat drugs which mimic branded products. it also makes generic medicines which are based on expired patents. indian made drugs can be more than 10% less than branned products. aid groups are applauding it saying it protects the right of the poor to medical treatment. >> i think the supreme court has protected the practice. >> but the company's growing drug industry is raising concerns. anlists point out that cheap alternatives from india could make it difficult for pharmaceutical companies to continue the expensive development of new medicines. responding to the court decision novartis released a statement saying that patents a safe guard innovation and encourage progress. the company sees the ruling as a

in this case, 40 countries had recognized the patent that novartis had claimed. that is a little different though then sometimes the argument we hear, which is whether the primary patent should be upheld. in this case, it was a follow-on patent, not the basic patent. it is a secondary patent. >> yes, so whether after a certain number of years, the patent should expiry. >> and whether you get a related patent, if the relationship is enough to warrant a new patent. that is really what this case is about. >> do we know how much research and development of a drug actually costs? the profits that drug companies make and the amount that they spend on research and development, do we know what that equation looks like? >> you need to be careful to look at two pieces. one is what does it cost to invent a drug like this, but the willd is how many misses the drug company have in order to capture a drug. >> they may do research on a drug that never comes to something. >> actually, most of the money they spend never comes to fruition. >> what can they do to avoid the position

in the ruling handed down on monday, the court says the compound made by novartis is not novel enough to qualify for a patent. the company filed the case seven years ago. india has stricter pharmaceutical patent requirements than other nations. for example, it doesn't allow patents for tweaks to existing drugs. this common industry practice is -- india a major producer of copycat drugs which mimic branded products. it also makes generic medicines which are based on expired patents. indian-made alternatives can cost less than 10% the price of branded drugs. health officials believe that more than alf of the aids drugs used in developing nations come from india. aid groups are applauding the court decision saying it protects the right of the poor to medical treatment. >> i think the supreme court said they definitely abuse this practice of getting many patents on one drug. >> but the country's growing drug industry is raising concerns. analysts point out that cheap alternatives from india could make it difficult for pharmaceutical companies to continue the expensive development of new m

novartis disrupted the process where they steered patients towards a drug. and here is what norvart simpb s. the company disagrees with the way the government has characterized their conduct and stands behind their programs. and one detail, a very interesting note here. companies who break the law tend to get caught up and end up paying huge fines where the behavior seems to go on and just continue. >> thank you so much. >> thank you so much. >> simon, down to you. >> ratings agencies, standard and poors, and morgan stanley have settled two lawsuits dating back to the financial crisis. the lawsuits accuse them of hiding risky investments. macgr macgraw hill is the parent company. j.c. penney is also moving higher this lunchtime. the company confirming what david had first reported that it has lined up a 5-year financing package from goldman sachs. it is the latest move to sure up its finances without ak fising equity. >> crisis earnings fell as it absorbed the cost of launching new vehicles but it stood by its financial forecast. the company says it had near

novartis is up by 0.4 % in line with the market. now, this specific drug, this is a cancer drug, it's not too important for novartis in india, anyway. keep in mind it is losing patent protection in the rest of the world starting in 2014, anyway. why this is so significant? it is because it is a benchmark for other intellectual property cases in the world, maybe not just india, but also in other ee mermging markets. take a look at roach and pfizer, for example. they're still engaged in similar disputes in india and all the big pharmacy disputes. they're hoping to boost their sales in the emerging markets because they're still in developed markets and growth. let's talk about some of the ramifications for the big pharma companies. they cannot hope to make as much money in india, for example, going forward. but it is a big, big boost for the local drugmakers who can make those generic drugs and they can sell them at a tenth of the price. it's also a big victory for those patient necessary india, for example, who simply can't afford the

novartis says the decision will inhibit innovation. health insurers' stocks added healthy gains in advance of rulings on medical reimbursement rates. the ruling from the centers for medicare and medicaid services calls for reimbursement rates to climb more than 3%. earlier, it was expected the cost it pays insurers per person would fall more than 2% next year. one analyst reportedly predicts the revised rate will give medicare advantage plans more stability. humana led the way with a nearly 9% gain yesterday, closing at $75.02. small businesses are finding a new way to beat the rising cost of healthcare. many employers have started to barter medical services for employees. in exchange for medical services with doctors, dentists and pharmacies, businesses can actually trade a service for the cost of a procedure. "we found a way to incorporate using their barter accounts, their trade accounts as spifs or bonuses for their employees so that way they can contribute towards healthcare for them." that was nicole graham of trade international

that's what novartis is saying. back to you. liz: okay, thank you very much. capital is a huge hedge fund that the feds have been circling around. well, one of their top guys, michael steinberg, is pleading not guilty to insider trading charges. if you were not around good friday, he was arrested. here's a video of it. pulled right out of his new york park avenue apartment very early friday morning. but steinberg isn't the only one that the government is after. there are more above and then, of course, the top man that they are very interested in. seth is a managing partner, he's an attorney who's looked at a lot of white collar crimes, dealt with them. when you heard about what happened friday and what went down, that they yanked michael steinberg right out of his apartment on park avenue, put the cuffs on him, he wasn't allowed to turn himself in, no fancy treatment, you get treated like everybody else, what was your first thought? >> well, my first thought was that's an aggressive chess move by the federal prosecutor. looking at it in the big picture, we ha

novartis responded to today's decision by saying it will not invest in drug research there. calm returned to the streets of kisumu, kenya, today after a weekend of heavy rioting. the city is home to raila odinga, who narrowly lost the presidential race to uhuru kenyatta. on saturday, the supreme court confirmed kenyatta was the winner of the march 4 election. that announcement angered odinga supporters, who set tires on fire and blocked major roads. police responded by firing tear gas at the rioters. kenyatta is expected to be sworn in on april 9. stocks edged lower on wall street today in a light day of trading. the dow jones industrial average lost more than five points to close above 14,572. the nasdaq fell 28 points to close at 3,239. those are some of the day's major stories. now, back to margaret. >> warner: and to updates on two shootings, in texas, and in colorado. guards with semiautomatic weapons patrolled texas courthouses today, after kaufman county district attorney mike mclelland and his wife, cynthia, were murdered saturday night in their own home. it is the s

novartis had sought pented protection for a cancer drug in india since 2006. the case was seen as a critical test of in his ability to manufacture low-cost generic drugs that are distributed throughout the global sow to treat infectious diseases. earlier today, the medical charity doctors without borders praised the court's decision. >> it is a huge relief because we have more than 200,000 withe living with hiv treatment. this would mean [indiscernible] that a big relief for us the drugs are safe and secure and available to patients. >> on the eve of the ruling, novartis had tried to stop sending new medicine to india if the court did not decide in its favor. the judge will likely affect other major pharmaceutical companies and their drug brands in india. the philippines government is calling on the u.s. for compensation following the removal of a naval ship that was stuck on a pristine coral reef for 10 weeks. the u.s. as guardian was after its commanders ignored warnings from park rangers. the reef is a unesco world heritage site. at least 4000 square meters

it's been a week in which emerging markets are playing big for novartis.ow badly do you think novartis wants this brazilian company? >> it would make sense, wouldn't it? brazil is one of the fastest growing ining emerging economie. ache is the fourth biggest brazilian drug company by sales. leader in prescription medicine and also very active in the rapidly growing otc market. ache is a company which had 1.5 billion in sales last year and it has around 3,000 employees. it's a pretty big sized firm and the deal would also be fairly highly priced. you mentioned the number more than $5 billion is what the price tag could be looking like and that would suggest a multiple of between 15 and 20 times and that looks to be on the high side according to some analysts. the other bidders in this include pfizer and abbott labratories. there is uncertainty as to whether this deal would go through. that's because one of the families which has a controlling stake in the company is still not sure whether it actually wants to sell. kelly? >> okay. thank you very much. i lik

. >>> also overnight, a major setback for drug company novartis. india's highest court denied a patent petition for a cancer drug. this will surely impact the stock today. >>> this morning exxon mobil continues to clean up thousands of barrels of heavy crude oil that's been leaking in the town of mayflower, arkansas. the pipeline carries 90,000 barrels from illinois to texas every day. it was shut down on friday, and its residents from 22 homes were evacuated. >>> check out this vintage sergeant pepper's album color autographed by john, paul, george and ringo. it was sold at auction for a record $290,500. it's believed the fab four signed the album in june of 1967. >>> employers beware. better expect more than a few people calling out sick today. it's not an april fools' joke, but little opening day for baseball armed the country. >>> plus, bottoms up. a professional golfer drops his drawers on the green. >>> other stories that caught our eye this morning. the powerball winner is spreading the world. the $338 million winner has agreed to pay the re

novartis may be saying it is not what they wanted to be so let's take them out.t pushing drugs overly heavily towards doctors so that they will prescribe them. >> i did not know that you thought the government had a legitimate function. you are absolutely right. i have had previous suit about stuff like this. i think this was a rampant cultural problem. some pretty girl goes to her office, buys them a free lunch and then expects you to buy the drug. at a time, of course, where obamacare is causing austerity. stuart: do people contact you and say i am from so and so, let's go out to lunch. >> there is no question about it. they have been doing it for years. they will continue to do it. >> do we have no faith in our medical professionals anymore? do they think a lunch at hooters will get them to prescribe their medication? >> you are right. doctors can be savvy enough to say, here is a free sample, here is a free lunch, but i stick to my prescribing benefits. it is reprehensible for a doctor to be succumbing to this. stuart: do they give you free samples? >> absolu

india's supreme court has rejected drug maker novartis's right to patent a new version of a lifesavingling monday is a victory for india's $26 billion generic drug industry that provides cheap medicines to millions around the world. the ruling is a precedent that prevents international pharmaceutical companies from obtaining fresh patents in india on updated versions of existing drugs. advocates say such a ruling would help poor people get access to affordable, generic versions of lifesaving medicines. india's patent office had rejected the company's patent application because it was not a new medicine. south africa's government says former president nelson mandela has had a restful day in the hospital. a statement says he's improving after treatment for a recurrence of pneumonia. the office of the president thanked south africans who prayed for the 94-year-old mandela at easter church services this weekend. he also thanked foreign governments for "their messages of support." mandela was admitted to a hospital in pretoria on wednesday. it was his third trip to a hospital since december

. >>> also overnight, a major set back for drug company novartis.ia's highest court denied a patent for a cancer drug. >>> exxonmobile continues to clean up thousands of barrels of heavy crude oil that's been leaking in the town of mayflower, arkansas. the pipeline carries 90,000 barrels a day from illinois to texas. it was shut down friday. residents from 22 homes were evacuated. >>> check this out, it is a vintd taj "sergeant peppers i "album autographed for a whopping $290,000. it's believed that the fab four actually signed this album back in june of 1967. boy, that's a collector's item. >>> would you spend a cool million bucks if you could buy something that is worth 80 million bucks. it's an $80 million ice breaking ferry. it's for sale by the state of alaska. so far though, only one bid has come in and it's for just 751,000. you might have a deal on your hands if you're interested. >>> employers, beware. better expect more than a,000 people calling out sick. it is opening day around the nation. >>> plus, bottoms up. a professional golfer drop

one example: gleevec, made by novartis, which cost $30,000 a year in 2001, has more than tripled in price. some college-bound students are considering schools in canada. the number of u.s. students moving across the border is 50% higher than a decade ago. reports say canadain schools offer lower tuitions, allowing students to graduate with less debt. the popular university of winnipeg offers tuition for about $11,000 a year. an insider says students who graduate have access to top graduate programs around the globe. high school prom is turning into a pricey rite of passage. parents and teens will shell out an average of $1,139 on the event - that's up 40% from just a couple of years ago. the spending trend is said to be driven by pressure to post perfect pics on facebook and instagram. h&r block is offering $25 - and an apology - for refund delays. $25 prepaid debit cards will be sent to clients whose tax refunds were slowed by a software glitch. delays were caused by changes in the way the irs processes claims for education credits. it's unknown how many were affected, but h&r block says

hour, we will tell you what daniel oh day thinks about india's recent supreme court ruling against novartis, what it means for roach and what it means in the emerging markets. back over to you guys. >> karen, thanks very much indeed for that. let's bring you up to speed with where we stand right now in the global markets, what, an hour and 30 minutes into trade. we're just weighted to the upside 6 to 4 on the dow jones stocks 400. about the biggest daily rise for three months on wednesday following the record closes on the s&p and the dow, as well. right now, the ftse 100 pretty flat, pretty flat for the xetra dax. the ibex is down and the ftse mib is fairly flat, as well. spanish y50e8dz, 4.3%. we have seen the lows since 2010. there will be a question of how much more we can get with spanish debt. dollar/yen, 99.88 on late wednesday trade right now 99.6 2. there seems to be a lot of options barriers. and sixuan rejoins us today with a recap of what happens in asia. hi, sixuan. >> thank you, ross. the boj's big bazooka rally continued in japan with another sign of confidence. over in china

in a statement novartis confirms only that it is aware of the two losses filed by the u.s.ce in manhattan. the fda said fraudulent burgeons of botox are being sold in the u.s. agents are posting an alert warning that the our record it -- out for carbon is counterfeit and the vial is foreign and not approved for sale of the u.s. and samsung taking a bigger bite out of apple's share of the smart phone market with its cheaper android devices. according to research firm idc, samsung has had nearly 33 percent of the market in the latest quarter, almost twice the apple market share of 17%. now we continue our "countdown to the closing bell" with liz claman. ♪ liz: well, pretty much at highs of the session for the dow jones industrials. let's get to nicole petallides on the floor of the new york stock exchange to pick apart what moved the most this week. >> reporter: will take a look that the best percentage gainers on the dow jones industrials. this week we gained about 1902 points. but what names of the best performers in percentage terms? let's start off first with dupont's. du

n novartis is flat. not sure that we're showing the right walls. we'll get more in a few moment's time. as far as bond markets are concerned, the key point is looking at italy later today with the auction. 4.32%. treasury yields a little bit higher again at 1.76%. as far as currency markets are concerned, dollar/yen not on that 47-month low for dollar/yen. 99.43 is where we stand at the moment. euro/dollar 131.10 is up against the greenback. that's where we stand in european trade. >> a mildly positive day as investors shrugged off tensions in the korean peninsula. some say the weak external demand is already known factor. investors look out for more data due out later this week to get a better gauge. we saw profit taking despite strong q-1 profit but gas producers left support with expectations of a hike on natural gas prices. a positive finish on hang seng. look at commercial properties. stock surged four-fold after being suspended for more than a month. and in japan, the nikkei back on track of a rally. exporters and financials were broadly high

india's supreme court announced that novartis cannot pass the new cancer drug because it's not new. india makes more gentlemen makers than any -- generics than any other country. >> eric: verbal twengs between north korea and south korea. the u.s. is supporting its ally with a show of air power. joining us live from washington with the latest. >>> good morning. the standoff with north korea at this point is still a war of words. officials say the u.s. military is ready to respond to an attack. >> the warnings out of north korea this morning are increasingly provocative and ominous declaring a state of war with south korea as the nation's leader kim jong un gathered the supreme people's assembly. they declared nuclear weapons the nation's life and vowed not to trade them for billions of dollars. u.s. is taking the threat seriously deploying two fighter jets sunday from japan over south korea. a routine military drill meant as a show of force. >> we have a range of options to counter their provocations and threats. obviously we mope not to put those plans into effect. >> last week the

novartis? 6,000 a year. and quicksilver resources, the oil company. signed a deal to sell a stake.tually a subsidiary of tokyo gas. now the japanese are buying in. down about 40%. and 2013. looking like a good year so far for a company that was founded back in 1886. we're talking about johnson & johnson. they won big approval for a new diabetes drug. it is hitting an all time high today. does this widows and orphans stock, safe by slow growth, have more room to run in the upside? when ever i hear about a name like this hitting all time highs it makes me nervous. do i have reason to be? >> that's a great question. i think actually, i don't believe you have reason to be nervous just yet. j & j has been in the doldrums for the last year. i happen to think that certainly under new management, the new ceo, things are turning. it's about like that tanker up in maine. things are turning around. al beit a little bit slowly. you will also see opportunity for margin expansion. one comes from the pharmaceutical area and you mentioned it's a new diabetes drug. >> there are two ways to get that

. >>> sticking with news out of switzerland, stronger than expected sales for novartis.y tapped a new ceo and announced plans to shed 300 jobs in consumer health unit saying 2013 will be a year of transition. this comes shortly after the u.s. government filed a civil lawsuit against novartis alleging that one of the units had fraudulent payments from medicare and medicaid. the group is declinying the cla. they are lagging the market on this positive day down 0.4 of 1%. keep your thoughts coming here. you know how to reach us. worldwide@cnbc.com. over on the website today, you can read why jim o'neil won't put family's cash into bunds any time soon. you can read more of what the german wiseman has to say on cnbc.com. >>> sterling taking a bashing this year with yen following amongst majors but does the pound have legs to bounce back here? more details online ahead of tomorrow's first quarter gdp reading and you can follow us on twitter. we promise that we're protecting ourselves against hack. we'll be right back. >>> you're watching "worldwide exchange." welcome. these ar

drugmaker, novartis turned down in india for a new pattern of a cancer drug.ct its investment in the drug called glive. >>> health care activists are praising the supreme court decision to shut n var it is down so poorer patients have access to the life-setting medicine. it has global implications setting a precedent that will prevent international companies for maintaining new patents for medicine used in the developing world. >>> an 80-year-old man from japan will soon try to become the oldest person ever to race to the top of mt. everest. yuchiro miura will attempt to climb the mountain with a nine-person team. he has raced to the top twice in 2003 and '08. the climb will be dangerous, not only because of his age but he has had heart surgery four times. as of now, the oldest person to make the climb was 76 years old. >> go yuchiro. >>> take a look at what happened to a purse snatcher in australia. this man, bam, was running after taking a purpose from a woman at a mall in perth and suddenly crashes in and goes face down right into that on to the ground. peo

they have strong partnerships with larger players like novartis, decatur pharma, biogen, roche, glaxosmithkline, even monsanto. nice quarter today. it's revolutionary technology. again, ahead of the building blocks. the blueprints, the biggest drug candidates for a condition known as attr, a chronic, progressive, and often fatal form of amyloidosis. this drug is in phase two trials, could be worth $1.5 billion according to research we saw in peak sales to alnylam in the united states. if the company gets fda approval for this one, much higher. remember, playing fda roulette can be a dangerous game. they also have early stage drugs that might have a lot of potential like a severe hypercholesterolemia drug that's in phase one. could do $2 billion in peak sales, far away, though, and a hemophilia drug in phase one could do well. however, it will be years before the fda considers these two. finally, there is sangamo biosciences. a super speculative stock. market cap of just $500 million. small for us on the show. sangamo is a super high risk, high reward play. they have a proprietary technology pla

is suing novartis for allegedly paying kickbacks and providing lavish dinners to doctors. company is accused using payments to encourage doctors to prescribe their brand name drugs for hypertension and other medical conditions. no. >>> facebook ceo mark zuckerberg is adding tech heavyweights to his political advocacisy group. microsoft founder bill gates, steve ballmer and ceo brad smith and john parker have joined the project. that is today's speed reed. buzz wuz. liz: those are big names. being picked doesn't usually come just with bragging rights but it comes with a huge paycheck. jonathanning --ing has advise. >> you got to plan for future. >> amen, good advice. how do sport players plan? not very well when you look at stats. you're talking to one of the top sports advisors in the country and top sports agent about mistakes. that we all not just nfl players should avoid. ♪ thank you orville and wilbur... ...amelia... neil and buzz: for teaching us that you can't create the future... by clinging to the past. and with that: you're htory instead of looking behind... delta

plenty of companies, novartis, sanofi-aventis, they could team up and make a pandemic vaccine.could be big money. i don't think it's going to happen. stuart: headline in the wall street journal, a four-year-old boy recovered from a strain of bird flu that killed the people in china. that's good news, isn't it? >> absolutely. but pandemics, worldwide pandemi pandemics, caused by h-1, h-2, h-3, the protein on the surface of the virus. this is an h-7. as far as we know we've never seen a pandemic. we've got to worry, study this when people get sick, it does follow it's going to circulate like the movie "contagion". stuart: thank you, we appreciate it. i've got the 7 early movers, a lot of big news, deutsche telekom sweetens its bid for metropcs, and here is is a look at pcs, it's flat. and the network security company cut its outlook, it's down 16%, watch out. better than expected sales at the retailer zumiez and it's up. toyota, air bag recall, but the stock $112 a share, i'm sure that's because the yen is all the way down and they're going to sell more here. strong sales and bet

. >> every view will provide a treatment to a child to malaria thanks to hbo and novartis. a great cause, saving the lives of children and improving life for so many people in africa and other countries. the other element to this is the stronger and healthier people are in these countries the morey distant they are to forces of terrorism, for example which are becoming an increasing concern obviously in so many places in africa and the stronger the economy. the argument is that it behooves the rest of the world to may attention. bill: this is something we could eradicate in our lifetimes. martha: and they are working on it. bill: did we or did we not stop the chance to stop the boston bombers: they are talking about what watch list the tsarnaev brothers were or were not on. details on what we're learning with that in three minutes. ♪ [ male announcer ] just when you thought you had experienced performance a new ride comes along and changes everything. the 2013 lexus gs. this is the pursuit of perfection. [ female announcer ] from more efficient payments. ♪ to more efficient

and india's top court has dismissed novartis's attempt to win patent protection for a cancer drug. the decision is said to be a serious blow to the western pharmaceutical industry as the ruling likely affects several other countries and their brand ed drugs. the high court decision sets a benchmark for intellectual property disputes in india, as well. >> why don't we get a check on the markets. we showed you that futures were a little weaker this morning. right now, dow futures down by less than 11 points fair value. and, again, this is coming after gains on friday with the s&p 500 finally pushing through to an all-time high by the close of the day, tend of the quarter. first day of the new quarter and we'll see where things are head. oil prices are down by 52 cents to 96.71. the ten-year note is yielding 1.68%. the dollar this morning, we've been watching the dollar/euro sokosly because of cyprus. the dollar is weaker against the euro. the dollar/yen is at 93.49. it's worth pointing out that in the first quarter, the yen was down 8.5% against the dollar. you can see right now, gol

it was made by a former novartis employee.pant in speaker program which is an accepted practice designed to inform doctors about the appropriate use of medicines. >> carl. >> the instinct is to say this goes on all the time in the pharma business, in the medical business, but we don't get many excuses to run that kind of video, david. >> no, we don't. >> can you explain the appropriate use of a medicine whilest at a hooters? i would hope -- >> we've got to talk about the medicines and then we'll get on to, i don't know, probably nothing. >> it also comes on a day when "usa today" fronts on their business section, i might add, guys, a proposed changes in the way the restaurant is designed. the logo apparently the owl is safe but there could be changes to the costume. they're thinking maybe something that looks more like a skirt than shorts. >> more tasteful. >> yes. >> sure. >> i don't know. you got the idea or not. but it's a good story on the "b" section in "usa today." thanks, david. >> carl, my pleasure. whatever i can do f